188 related articles for article (PubMed ID: 24383395)
1. Dual small-molecule targeting of procaspase-3 dramatically enhances zymogen activation and anticancer activity.
Botham RC; Fan TM; Im I; Borst LB; Dirikolu L; Hergenrother PJ
J Am Chem Soc; 2014 Jan; 136(4):1312-9. PubMed ID: 24383395
[TBL] [Abstract][Full Text] [Related]
2. Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy.
Putt KS; Chen GW; Pearson JM; Sandhorst JS; Hoagland MS; Kwon JT; Hwang SK; Jin H; Churchwell MI; Cho MH; Doerge DR; Helferich WG; Hergenrother PJ
Nat Chem Biol; 2006 Oct; 2(10):543-50. PubMed ID: 16936720
[TBL] [Abstract][Full Text] [Related]
3. Targeting procaspase-3 with WF-208, a novel PAC-1 derivative, causes selective cancer cell apoptosis.
Wang F; Liu Y; Wang L; Yang J; Zhao Y; Wang N; Cao Q; Gong P; Wu C
J Cell Mol Med; 2015 Aug; 19(8):1916-28. PubMed ID: 25754465
[TBL] [Abstract][Full Text] [Related]
4. Procaspase-3 activation as an anti-cancer strategy: structure-activity relationship of procaspase-activating compound 1 (PAC-1) and its cellular co-localization with caspase-3.
Peterson QP; Hsu DC; Goode DR; Novotny CJ; Totten RK; Hergenrother PJ
J Med Chem; 2009 Sep; 52(18):5721-31. PubMed ID: 19708658
[TBL] [Abstract][Full Text] [Related]
5. Targeting executioner procaspase-3 with the procaspase-activating compound B-PAC-1 induces apoptosis in multiple myeloma cells.
Zaman S; Wang R; Gandhi V
Exp Hematol; 2015 Nov; 43(11):951-962.e3. PubMed ID: 26257207
[TBL] [Abstract][Full Text] [Related]
6. Parallel synthesis and biological evaluation of 837 analogues of procaspase-activating compound 1 (PAC-1).
Hsu DC; Roth HS; West DC; Botham RC; Novotny CJ; Schmid SC; Hergenrother PJ
ACS Comb Sci; 2012 Jan; 14(1):44-50. PubMed ID: 22007686
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and derivation of an anticancer dosing regimen for PAC-1, a preferential small molecule activator of procaspase-3, in healthy dogs.
Lucas PW; Schmit JM; Peterson QP; West DC; Hsu DC; Novotny CJ; Dirikolu L; Churchwell MI; Doerge DR; Garrett LD; Hergenrother PJ; Fan TM
Invest New Drugs; 2011 Oct; 29(5):901-11. PubMed ID: 20499133
[TBL] [Abstract][Full Text] [Related]
8. The Combination of Vemurafenib and Procaspase-3 Activation Is Synergistic in Mutant BRAF Melanomas.
Peh J; Fan TM; Wycislo KL; Roth HS; Hergenrother PJ
Mol Cancer Ther; 2016 Aug; 15(8):1859-69. PubMed ID: 27297867
[TBL] [Abstract][Full Text] [Related]
9. Discovery and canine preclinical assessment of a nontoxic procaspase-3-activating compound.
Peterson QP; Hsu DC; Novotny CJ; West DC; Kim D; Schmit JM; Dirikolu L; Hergenrother PJ; Fan TM
Cancer Res; 2010 Sep; 70(18):7232-41. PubMed ID: 20823163
[TBL] [Abstract][Full Text] [Related]
10. Synergistic antitumor activity of pro-apoptotic agent PAC-1 with cisplatinum by the activation of CASP3 in pulmonary adenocarcinoma cell line H1299.
Huang JQ; Liang HL; Zhang XC; Xie Z; Jin TE
Asia Pac J Clin Oncol; 2016 Mar; 12(1):41-51. PubMed ID: 26620316
[TBL] [Abstract][Full Text] [Related]
11. SM-1, a novel PAC-1 derivative, activates procaspase-3 and causes cancer cell apoptosis.
Chen Y; Sun M; Ding J; Zhu Q
Cancer Chemother Pharmacol; 2016 Sep; 78(3):643-54. PubMed ID: 27488460
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of procaspase-3 activating compounds in the induction of cancer cell death.
West DC; Qin Y; Peterson QP; Thomas DL; Palchaudhuri R; Morrison KC; Lucas PW; Palmer AE; Fan TM; Hergenrother PJ
Mol Pharm; 2012 May; 9(5):1425-34. PubMed ID: 22486564
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of paclitaxel is significantly enhanced by a novel proapoptotic agent in non-small cell lung cancer.
Razi SS; Rehmani S; Li X; Park K; Schwartz GS; Latif MJ; Bhora FY
J Surg Res; 2015 Apr; 194(2):622-630. PubMed ID: 25498514
[TBL] [Abstract][Full Text] [Related]
14. Procaspase-activating compound 1 induces a caspase-3-dependent cell death in cerebellar granule neurons.
Aziz G; Akselsen ØW; Hansen TV; Paulsen RE
Toxicol Appl Pharmacol; 2010 Sep; 247(3):238-42. PubMed ID: 20638399
[TBL] [Abstract][Full Text] [Related]
15. Procaspase-Activating Compound-1 Synergizes with TRAIL to Induce Apoptosis in Established Granulosa Cell Tumor Cell Line (KGN) and Explanted Patient Granulosa Cell Tumor Cells In Vitro.
Crosley P; Farkkila A; Jenner AL; Burlot C; Cardinal O; Potts KG; Agopsowicz K; Pihlajoki M; Heikinheimo M; Craig M; Fu Y; Hitt MM
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946730
[TBL] [Abstract][Full Text] [Related]
16. Molecular evidence of Zn chelation of the procaspase activating compound B-PAC-1 in B cell lymphoma.
Sarkar A; Balakrishnan K; Chen J; Patel V; Neelapu SS; McMurray JS; Gandhi V
Oncotarget; 2016 Jan; 7(3):3461-76. PubMed ID: 26658105
[TBL] [Abstract][Full Text] [Related]
17. Cell death induced by novel procaspase-3 activators can be reduced by growth factors.
Boldingh Debernard KA; Aziz G; Gjesvik AT; Paulsen RE
Biochem Biophys Res Commun; 2011 Sep; 413(2):364-9. PubMed ID: 21893038
[TBL] [Abstract][Full Text] [Related]
18. Removal of Metabolic Liabilities Enables Development of Derivatives of Procaspase-Activating Compound 1 (PAC-1) with Improved Pharmacokinetics.
Roth HS; Botham RC; Schmid SC; Fan TM; Dirikolu L; Hergenrother PJ
J Med Chem; 2015 May; 58(9):4046-65. PubMed ID: 25856364
[TBL] [Abstract][Full Text] [Related]
19. Potential small-molecule activators of caspase-7 identified using yeast-based caspase-3 and -7 screening assays.
Pereira C; Lopes-Rodrigues V; Coutinho I; Neves MP; Lima RT; Pinto M; Cidade H; Vasconcelos MH; Saraiva L
Eur J Pharm Sci; 2014 Apr; 54():8-16. PubMed ID: 24398107
[TBL] [Abstract][Full Text] [Related]
20. PAC-1 activates procaspase-3 in vitro through relief of zinc-mediated inhibition.
Peterson QP; Goode DR; West DC; Ramsey KN; Lee JJ; Hergenrother PJ
J Mol Biol; 2009 Apr; 388(1):144-58. PubMed ID: 19281821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
